Fulgent Genetics (FLGT) AI Stock Analysis

• Market Cap: $932.01M
• Dividend Yield: N/A
• Average Volume (3M): 342.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.29
• Revenue Growth: 13.60%
• EPS Growth: 74.64%
• Country: US
• Employees: 1,313
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.14
• Shares Outstanding: 30,912,392
• 10 Day Avg. Volume: 404,077
• 30 Day Avg. Volume: 342,051
• PEG Ratio: 0.17
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 1.97
• P/FCF Ratio: -29.00
• Enterprise Value/Market Cap: 0.35
• Enterprise Value/Revenue: 1.02
• Enterprise Value/Gross Profit: 2.47
• Enterprise Value/Ebitda: -10.30
• 1Y Price Target: $32.50
• Price Target Upside: 9.87% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 0.26
• Revenue Forecast (FY): $322.88M

• Rating: 60 Neutral
• Price Target: $28.00 ▼(-5.34% Downside)

The overall stock score is primarily influenced by the positive outlook from the earnings call, which highlights growth in laboratory services and strategic advancements. However, financial performance and valuation concerns, such as declining profitability and a negative P/E ratio, weigh down the score. Technical analysis shows bullish momentum, but overbought conditions suggest caution.

Positive Factors

Revenue Growth

A 15% revenue growth outlook indicates strong demand for Fulgent's services, suggesting robust market positioning and potential for sustained expansion.

Product Innovation

Innovative product launches enhance Fulgent's competitive edge, potentially increasing market share and improving patient outcomes in genomic diagnostics.

Therapeutic Development

Advancements in therapeutic development, like FID-007, can open new revenue streams and strengthen Fulgent's position in precision medicine.

Negative Factors

Cash Flow Challenges

Declining cash flow growth can limit Fulgent's ability to invest in new projects and technologies, potentially hindering future growth and operational flexibility.

Declining Profitability

Sustained unprofitability reflects operational inefficiencies and can strain financial resources, impacting long-term viability and investor confidence.

GAAP Loss

Continued GAAP losses highlight financial struggles, suggesting the need for strategic adjustments to achieve profitability and maintain investor trust.

Fulgent Genetics Business Overview & Revenue Model

Company Description

Fulgent Genetics, Inc. is a technology company focused on providing comprehensive genetic testing solutions to various sectors including healthcare and research. Specializing in genomic testing, the company offers a wide range of services including DNA sequencing, variant analysis, and custom genetic testing services. Fulgent's advanced platform is designed to deliver accurate and rapid diagnostic results for inherited diseases, infectious diseases, and cancer, thereby supporting clinical decision-making and personalized medicine.

How the Company Makes Money

Fulgent Genetics generates revenue primarily through its genetic testing services, which include various forms of genomic analysis for patients and healthcare providers. The company operates a business model that relies on the sale of its testing kits, laboratory services, and data analytics solutions. Key revenue streams include reimbursement from insurance companies for tests performed, direct payments from healthcare providers, and partnerships with hospitals and clinics that utilize Fulgent's testing solutions for their patients. Additionally, Fulgent has established collaborations with pharmaceutical companies and research institutions, which further enhances its earning potential through joint ventures and research agreements.

Fulgent Genetics Financial Statement Overview

Summary

Fulgent Genetics is facing financial difficulties with declining revenues and profitability since 2021. The balance sheet remains strong with low leverage, but cash flow issues are concerning. The company needs to address operational inefficiencies and improve cash generation to stabilize its financial position.

Income Statement

Fulgent Genetics has experienced a significant decline in revenue and profitability over the past few years. The TTM data shows a slight revenue growth of 4.07%, but the company is still operating at a loss with a net profit margin of -13.62%. Historical data reveals a sharp decline from 2021, when the company had a net profit margin of 51.12%. The EBIT and EBITDA margins have also deteriorated, indicating operational challenges.

Balance Sheet

The balance sheet remains relatively strong with a very low debt-to-equity ratio of 0.0004 in the TTM period, indicating minimal leverage. However, the return on equity is negative at -3.82%, reflecting the company's current unprofitability. The equity ratio is stable, suggesting a solid capital structure despite recent losses.

Cash Flow

Cash flow metrics indicate challenges, with a significant decline in free cash flow growth and a negative free cash flow to net income ratio of -13.03 in the TTM period. The operating cash flow to net income ratio is low at 0.021, highlighting cash generation issues. Historical data shows a drastic reduction in free cash flow from 2021 levels.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	315.55M	283.47M	289.21M	618.97M	992.58M	421.71M
Gross Profit	130.14M	107.22M	104.46M	366.90M	777.05M	331.90M
EBITDA	-31.26M	-48.99M	-147.45M	217.70M	686.96M	293.12M
Net Income	-42.98M	-42.71M	-167.82M	143.40M	507.36M	214.31M
Balance Sheet
Total Assets	1.21B	1.22B	1.24B	1.39B	1.28B	700.46M
Cash, Cash Equivalents and Short-Term Investments	375.80M	258.11M	424.15M	526.24M	450.50M	299.37M
Total Debt	7.54M	8.47M	15.25M	38.94M	21.28M	15.85M
Total Liabilities	93.81M	90.81M	102.04M	116.18M	112.84M	131.07M
Stockholders Equity	1.13B	1.13B	1.14B	1.27B	1.16B	569.39M
Cash Flow
Free Cash Flow	-19.85M	-19.25M	4.80M	234.75M	514.73M	104.12M
Operating Cash Flow	1.52M	21.06M	27.00M	253.52M	538.58M	140.63M
Investing Cash Flow	72.76M	-58.35M	38.90M	-261.31M	-546.55M	-326.44M
Financing Cash Flow	-14.58M	-4.85M	-47.78M	-77.14M	85.41M	261.25M

Fulgent Genetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 29.58
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FLGT, the sentiment is Positive. The current price of 29.58 is above the 20-day moving average (MA) of 27.51, above the 50-day MA of 24.70, and above the 200-day MA of 20.61, indicating a bullish trend. The MACD of 1.77 indicates Negative momentum. The RSI at 66.27 is Neutral, neither overbought nor oversold. The STOCH value of 69.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FLGT.

Fulgent Genetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	77 Outperform	$883.61M	14.41	24.11%	―	14.46%	―
FLGT	60 Neutral	$932.01M	―	-3.80%	―	13.60%	74.64%
CSTL	60 Neutral	$1.17B	―	-2.69%	―	10.15%	-295.52%
PSNL	57 Neutral	$952.87M	―	-43.69%	―	-21.02%	47.74%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LAB	49 Neutral	$454.57M	-3.72	-24.63%	―	-17.37%	52.28%
MYGN	49 Neutral	$708.42M	―	-72.52%	―	0.21%	-233.51%

Fulgent Genetics Corporate Events

Fulgent Genetics’ Earnings Call Highlights Growth and Innovation

Fulgent Genetics’ recent earnings call conveyed a positive sentiment, highlighting significant growth in laboratory services and advancements in therapeutic development. Despite facing challenges with Anatomic Pathology collections and reporting a GAAP loss, the company’s overall financial health and strategic initiatives indicate strong momentum moving forward.

Fulgent Genetics Reports Strong Q3 2025 Growth

Fulgent Genetics, Inc. is a technology-driven company operating in the laboratory services and therapeutic development sectors, focusing on cancer treatment innovations through its nanoencapsulation and targeted therapy platform.

Fulgent Genetics Raises 2025 Revenue Guidance

Fulgent Genetics reported its third quarter 2025 financial results, showing a revenue of $84.1 million, a 17% increase year-over-year, and a GAAP loss of $6.6 million. The company raised its full-year 2025 revenue guidance to $325.0 million and expects to end the year with approximately $800.0 million in cash and investments, demonstrating strong momentum in its laboratory services and therapeutic development businesses.

The most recent analyst rating on (FLGT) stock is a Hold with a $25.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.

Fulgent Genetics Presents Promising Phase 2 Trial Data

On October 20, 2025, Fulgent Genetics announced preliminary clinical data from its ongoing phase 2 trial of FID-007 in combination with cetuximab for treating recurrent or metastatic head and neck squamous cell carcinoma. The data, presented at the ESMO 2025 Conference, showed promising anticancer efficacy and a favorable safety profile, suggesting potential advancements in oncology treatments. This development supports Fulgent’s mission to provide comprehensive cancer care solutions, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (FLGT) stock is a Hold with a $23.00 price target. To see the full list of analyst forecasts on Fulgent Genetics stock, see the FLGT Stock Forecast page.